We and others have identified the Src and the MAPK pathways as alternative, targetable pathways in thyroid cancer and importantly, represent a potential therapeutic strategy for targeting thyroid cancers with various oncogenic drivers [11,12,30,31]. The gene discussed is SRC; the disease is thyroid gland carcinoma.